Intervention
SHR3680
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 8 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
8 shownA Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical ProstatectomyNCT05009290 · 2021-11-01
TERMINATEDDrug-durg Interaction of SHR3680 With Digoxin, Rosuvastatin Calcium and Metformin HydrochlorideNCT04621669 · 2021-01-08
COMPLETEDA Study of SHR3680 in Combination With Docetaxel in the Treatment of mCRPCNCT04603833 · 2020-12-02
UNKNOWNMolecularly Targeted Umbrella Study in Luminal Advanced Breast CancerNCT04355858 · 2020-05-01
UNKNOWNA Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPCNCT04102124 · 2019-04-08
TERMINATEDA Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPCNCT03741712 · 2018-11-20
TERMINATEDA Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate CancerNCT03520478 · 2018-05-30
UNKNOWNA Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer PatientsNCT02691975 · 2016-04-12
UNKNOWNCommon conditions
Prostate Cancer3Castration-resistant Prostate Cancer2Breast Cancer1Drug-drug Interaction,SHR36801Hormone Refractory Prostate Cancer1Hormone-Dependent Prostate Cancer1Metastatic Cancer1Metastatic Prostate Carcinoma1Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy1Prostate Cancer Metastatic1
Leading sponsors
Trial status mix
UNKNOWN4
TERMINATED3
COMPLETED1
Phase mix
PHASE25
PHASE13
PHASE32
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.